An FDA advisory panel voted narrowly to recommend four unapproved peptides, Bpc-157, Kpv, Tb-500, and Mots-c, be allowed for compounding by pharmacies. The votes came over the objections of FDA career scientists, who said they lacked the evidence to assess the compounds' safety and effectiveness. "All committee members underwent the same ethics review and vetting process required of all FDA advisory committee members," said Emily Hilliard, a HHS spokesperson, adding that candidates who could not meet existing ethics requirements were removed from consideration.2What did FDA scientists say? According to reports, FDA staff repeatedly came back to a foundational problem: it is unclear, chemically, what these peptides even are. Dr. Haleem Mohammed, chief medical officer at Gameday Men's Health, a Florida men's health clinic that offers peptides, voted yes for Bpc-157 on those grounds.